{"version":"1.0","provider_name":"Business France at BIO Convention","provider_url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention","title":"Netris Pharma - Business France at BIO Convention","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Y32wo0nACn\"><a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/netris-pharma-2\/\">Netris Pharma<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/netris-pharma-2\/embed\/#?secret=Y32wo0nACn\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Netris Pharma\u00a0\u00bb &#8212; Business France at BIO Convention\" data-secret=\"Y32wo0nACn\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Design-sans-titre-40.png","thumbnail_width":1350,"thumbnail_height":1350,"description":"Netris Pharma was founded by the pioneers of Dependence Receptors and its mission is to provide cancer patients with new treatment solutions able to overcome resistance to chemo- and Immunotherapies. The company is currently developing NP137, a first-in-class monoclonal antibody targeting Netrin1, a new untapped oncology target aberrantly expressed in multiple tumor types. Netrin1 has been showed to promote Epithelial-Mesenchymal Transition (EMT) and by disrupting the binding of Netrin1 to its receptors, NP137 is arguably the first compound able to break the deadlock of EMT to reduce metastasis and block resistance to cancer treatment. The product benefits from an excellent safety profile in monotherapy and in combination, and has already shown signs of antitumoral activity. In particular, the LAPNET study of NP137 in combination with mFolfirinox in Pancreatic cancer patients revealed neogenin as a potential predictive biomarker and opened a path for a biomarker-driven development in PDAC. Beyond PDAC, interim efficacy data in HNSCC and HCC further illustrate the potential of the product across solid tumors and strengthen the committment to advance NP137 as a new treatment option to address patient populations with high unmet medical need."}